Cargando…
Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed/refractory diffuse large B-cell lymphoma
BACKGROUND: Tisagenlecleucel demonstrated a high rate of durable response in adult patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL) in the pivotal global phase 2 JULIET study. Here, we report the efficacy and safety of tisagenlecleucel in the Japanese subgroup. METHODS:...
Autores principales: | Goto, Hideki, Makita, Shinichi, Kato, Koji, Tokushige, Kota, Fujita, Taizo, Akashi, Koichi, Izutsu, Koji, Teshima, Takanori |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Singapore
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7441082/ https://www.ncbi.nlm.nih.gov/pubmed/32448949 http://dx.doi.org/10.1007/s10147-020-01699-6 |
Ejemplares similares
-
Efficacy and safety of tisagenlecleucel in adult Japanese patients with relapsed or refractory follicular lymphoma: results from the phase 2 ELARA trial
por: Fukuhara, Noriko, et al.
Publicado: (2022) -
Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphoma
por: Kato, Koji, et al.
Publicado: (2021) -
Zandelisib (ME-401) in Japanese patients with relapsed or refractory indolent non-Hodgkin’s lymphoma: an open-label, multicenter, dose-escalation phase 1 study
por: Goto, Hideki, et al.
Publicado: (2022) -
Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma
por: Jaeger, Ulrich, et al.
Publicado: (2022) -
Forodesine in the treatment of relapsed/refractory peripheral T-cell lymphoma: an evidence-based review
por: Makita, Shinichi, et al.
Publicado: (2018)